Renal cell carcinoma

Active Ingredient: Nivolumab

Indication for Nivolumab

Population group: only adults (18 years old or older)

Therapeutic intent: Curative procedure

Nivolumab as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

For this indication, competent medicine agencies globally authorize below treatments:

240 mg every 2 weeks or 480 mg every 4 weeks

For:

Dosage regimens

Regimen A: Intravenous, 240 milligrams nivolumab, once every 2 weeks.

Regimen B: Intravenous, 480 milligrams nivolumab, once every 4 weeks.

Detailed description

240 mg every 2 weeks over 30 minutes or 480 mg every 4 weeks over 60 minutes.

If patients need to be switched from the 240 mg every 2 weeks schedule to the 480 mg every 4 weeks schedule, the first 480 mg dose should be administered two weeks after the last 240 mg dose. Conversely, if patients need to be switched from the 480 mg every 4 weeks schedule to the 240 mg every 2 weeks schedule, the first 240 mg dose should be administered four weeks after the last 480 mg dose.

Dosage considerations

Nivolumab must not be administered as an intravenous push or bolus injection.

Active ingredient

Nivolumab
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth. Read more about Nivolumab

Related medicines

Summary of Product Characteristics (SPC) 2024: OPDIVO Concentrate for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.